Transglutaminase 2 transamidation activity during first-phase insulin secretion: natural substrates in INS-1E
- 616 Downloads
Transglutaminase 2 (TG2) is a multifunctional protein with Ca2+-dependent transamidating and G protein activity. Previously, we reported that tgm2 −/− mice have an impaired insulin secretion and that naturally occurring TG2 mutations associated with familial, early-onset type 2 diabetes, show a defective transamidating activity. Aim of this study was to get a better insight into the role of TG2 in insulin secretion by identifying substrates of TG2 transamidating activity in the pancreatic beta cell line INS-1E. To this end, we labeled INS-1E that are capable of secreting insulin upon glucose stimulation in the physiologic range, with an artificial acyl acceptor (biotinamido-pentylamine) or donor (biotinylated peptide), in basal condition and after stimulus with glucose for 2, 5, and 8 min. Biotinylated proteins were analyzed by two-dimensional electrophoresis and mass spectrometry. In addition, subcellular localization of TG2 in human endocrine pancreas was studied by electron microscopy. Among several TG2’s transamidating substrates in INS-1E, mass spectrometry identified cytoplasmic actin (a result confirmed in human pancreatic islet), tropomyosin, and molecules that participate in insulin granule structure (e.g., GAPDH), glucose metabolism, or [Ca2+] sensing (e.g., calreticulin). Physical interaction between TG2 and cytoplasmic actin during glucose-stimulated first-phase insulin secretion was confirmed by co-immunoprecipitation. Electron microscopy revealed that TG2 is localized close to insulin and glucagon granules in human pancreatic islet. We propose that TG2’s role in insulin secretion may involve cytoplasmic actin remodeling and may have a regulative action on other proteins during granule movement. A similar role of TG2 in glucagon secretion is also suggested.
KeywordsTransglutaminase 2 Insulin secretion Calcium β-Cell INS-1E Human islet
Part of this work has been supported by the Telethon grants GGP09147 to Ornella Massa and by Swiss National Science Foundation to Pierre Maechler. Authors are grateful to Prof. F. Barbetti for his continuous support and helpful contribution to discussion, to Prof. C. Capella (Department of Human Morphology and Department of Pathology, Ospedale di Circolo, Varese, Italy), to Prof. M. Piacentini (Department of Biology, University of Rome “Tor Vergata”, Rome, Italy), Dr. G.M. Fimia and Dr. F. Ciccosanti (National Institute for Infectious Diseases, IRCCS “L. Spallanzani”, Rome, Italy) for MALDI TOF experiments on A25 labeled substrates and to Dr. C. Placidi (Department of Human Morphology, University of Insubria and Department of Pathology, Ospedale di Circolo, Varese, Italy) for helping with human pancreas microscopy.
Conflicts of interest
No potential conflicts of interest relevant to this article were reported.
- 9.Bernassola F, Federici M, Corazzari M, Terrinoni A, Hribal ML, De Laurenzi V, Ranalli M, Massa O, Sesti G, McLean WHI, Citro G, Barbetti F, Melino G (2002) Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient. FASEB J 16:1278–1371CrossRefGoogle Scholar
- 11.Gallwitz B, Kazda C, Kraus P, Nicolay C, Schernthaner G (2011) Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes. Acta Diabetol. doi: 10.1007/s00592-011-0319-4
- 12.Porzio O, Massa O, Cunsolo V, Colombo C, Malaponti M, Bertuzzi F, Hansen T, Johansen A, Pedersen O, Meschi F, Terrinoni A, Melino G, Federici M, Decarlo N, Menicagli M, Campani D, Marchetti P, Ferdaoussi M, Froguel P, Federici G, Vaxillaire M, Barbetti F (2007) Missense mutations in the TGM2 gene encoding transglutaminase 2 are found in patients with early-onset type 2 diabetes. Hum Mutat 28:1150PubMedCrossRefGoogle Scholar
- 28.Selway JL, Moore CE, Mistry R, R. A. John Challiss, Herbert TP (2011) Molecular mechanisms of muscarinic acetylcholine receptor–stimulated increase in cytosolic free Ca2+ concentration and ERK1/2 activation in the MIN6 pancreatic β-cell line. Acta Diabetol. doi: 10.1007/s00592-011-0314-9
- 31.D’Hertog W, Overbergh L, Lage K, Ferriera GB, Maris M, Gysemans C, Flamez D, Kupper Cardozo A, Van den Bergh G, Schoofs L, Lut Arckens L, Moreau Y, Hansen D, Eizirik DL, Waelkens E, Mathieu C (2007) Proteomics analysis of cytokine-induced dysfunction and death in insulin-producing INS-1E cells. New insights into the pathways involved. Mol Cell Proteom 6:2180–2199CrossRefGoogle Scholar
- 32.La Rosa S, Lloyd RV, Capella C (2005) Expression and role of myosins in pancreatic endocrine cells and related tumors. In: Trends in Pancreatic Cancer Research. Maxwell A. Loft, ed. Nova Science Publishers, Inc., New York, p 23–39Google Scholar
- 46.Bowling P, O’Driscoll L, O’Sullivan F, Dowd A, Henry M, Jeppesen PB, Meleady P, Clynes M (2006) Proteomic screening of glucose-responsive and glucose non-responsive MIN-6 beta cells reveals differential expression of proteins involved in protein folding, secretion and oxidative stress. Proteomics 6:6578–6587CrossRefGoogle Scholar